$FLNA News

Maxim Group Reinstates Buy on Filana Therapeutics, Announces $5 Price Target

Filana Therapeutics Q1 EPS $(0.21) Beats $(0.23) Estimate

Filana Therapeutics Announces Publication In Epilepsia Of Preclinical Data Showing Simufilam Attenuated Seizure Progression In Mouse Model Of Severe TSC-Related Epilepsy

Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Cassava Sciences Changes Name To Filana Therapeutics, Ticker To FLNA, Effective March 11

Cassava Sciences Says U.S. DOJ Fraud Section Closes Its Inquiry Into The Company Regarding Allegations Of Research Misconduct

Watching Cassava Sciences; Traders Circulate Co Files New Trademark For "FILANA THERAPEUTICS", Suggesting A Possible Rebrand Or Maybe Something Else Coming

Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease

Cassava Sciences Announces Publication Of Article Phase 3 Randomized Clinical Trials Of Simufilam In Mild-To-Moderate Alzheimer's Disease In Upcoming Issue Of JPAD

Cassava Announces Agreement to Settle Securities Class Action Litigation

Cassava Closes Chapter On Investor Lawsuit With Around $31 Million Deal

Cassava Sciences Agrees To Resolve Consolidated Securities Class Action Litigation Pending In US District Court For Western District Of Texas Austin Division; Cassava To Pay $31.25M To Complete Settlement

FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold

Cassava Sciences shares are trading lower after the company announced the FDA placed a full clinical hold on its proposed clinical trial for simufilam in TSC-related epilepsy.

Cassava Sciences Says Not Expected To Initiate Proof-Of-Concept Clinical Trial For Simufilam In TSC-Related Epilepsy In H1 2026 As Previously Disclosed

On December 15, 2025, Cassava Sciences Received A Formal Letter From FDA Confirming That The Proposed Clinical Trial Is On Full Clinical Hold Subject To The Company Providing FDA With Additional Information

Cassava Sciences Received FDA Request for More Data On IND For Simufilam In TSC-Related Epilepsy Proof-of-Concept Trial

Cassava Pops After CEO Buys 150,000 Shares

Cassava Reports Q3 2025 Financials Results and Provides Business Update

Cassava Sciences Q3 EPS $(0.22) Beats $(0.27) Estimate